What is the current Price Target for the Tvardi Therapeutics stock?

The average Tvardi Therapeutics target price is $56.10. This is 65.58% higher than the current stock price. The highest price target is 141.74%, the lowest is 25.21%. 9 Analysts have issued a price target Tvardi Therapeutics 2026 .

How high will the Tvardi Therapeutics stock rise?

No reliable answer can be given as to how high the Tvardi Therapeutics stock will rise. The performance of stocks, including the Tvardi Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Tvardi Therapeutics stock today?

The performance of Tvardi Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Tvardi Therapeutics stock fall?

The decline in Tvardi Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Tvardi Therapeutics Forecast, price target & analysts

$33.88

4.29%

Nasdaq, Sep 12, 10:00 pm CET

ISIN

US1407553072

Symbol

TVRD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Tvardi Therapeutics Target price 2025 - Analyst rating & recommendation

Tvardi Therapeutics Classifications & Recommendation:

Buy

92%

Hold

Tvardi Therapeutics Price Target

Target Price	$56.10
Price	$33.88
Potential	65.58% register free of charge
Number of Estimates	9

	9 Analysts have issued a price target Tvardi Therapeutics 2026 . The average Tvardi Therapeutics target price is $56.10. This is 65.58% register free of charge higher than the current stock price. The highest price target is $81.90 141.74% register free of charge , the lowest is $42.42 25.21% register free of charge .
	A rating was issued by 13 analysts: 12 Analysts recommend Tvardi Therapeutics to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Tvardi Therapeutics stock has an average upside potential 2026 of 65.58% register free of charge . Most analysts recommend the Tvardi Therapeutics stock at Purchase.

Current Tvardi Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Raymond James	Locked ➜ Locked	Locked	Jul 14 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	Jul 11 2025
Piper Sandler	Locked ➜ Locked	Locked	Jun 12 2025
Oppenheimer	Locked ➜ Locked	Locked	May 21 2025
Jones Trading	Locked ➜ Locked	Locked	Apr 28 2025

Analyst Rating	Date
Locked Raymond James: Locked ➜ Locked	Jul 14 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	Jul 11 2025
Locked Piper Sandler: Locked ➜ Locked	Jun 12 2025
Locked Oppenheimer: Locked ➜ Locked	May 21 2025
Locked Jones Trading: Locked ➜ Locked	Apr 28 2025

Discover more stocks with a high price target

Novo Nordisk 46.43%

BioNTech SE - ADR 43.92%

Deutsche Telekom 29.16%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now

The Apple stock at a glance with charts, current key metrics, news and stock analyses.

The Best Dividend Stocks in the Dividend Top Scorer list.

Stock Analyses of the Best Stocks Worldwide.

Start building wealth today